{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000150","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.232824+00:00","generated_at":"2026-05-28T03:25:59.952055+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Corvus reports soquelitinib Phase 1 atopic dermatitis data: 26% IGA 0/1, 37% EASI 75 vs 0% placebo","bullets":["19 soquelitinib patients: 26% achieved IGA 0/1, 37% achieved EASI 75 at day 28.","Placebo group (n=7) had 0% achieving IGA 0/1 or EASI 75.","No significant safety issues; all 10 Cohort 2 patients completed 28-day full 200 mg once-daily dose.","Cohort 2 fully enrolled (N=16); full results from all four cohorts expected Q2 2025.","Soquelitinib 200 mg twice-daily dose being studied in Phase 3 for peripheral T cell lymphoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000150","json":"https://secwatch.observer/filing/0001558370-25-000150.json","markdown":"https://secwatch.observer/filing/0001558370-25-000150.md","text":"https://secwatch.observer/filing/0001558370-25-000150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000155837025000150/0001558370-25-000150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000155837025000150/crvs-20250113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:25:59.952055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}